orphan drug

(redirected from Orphan drugs)
Also found in: Dictionary, Medical.
Related to Orphan drugs: orphan disease

orphan drug,

drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the development and manufacturing of such drugs, which otherwise might not be profitable because of the small potential market. (Of the 5,000 diseases covered under the act, 47% affect fewer than 25,000 people.) The law has led to the introduction of valuable new drugs for the treatment of rare diseases, but some drug companies have been accused of abusing the law's provisions by making inordinately high profits on orphan drugs under monopoly. Since the 1983 act went into effect, many orphan drugs have been approved, including those for the treatment of such conditions as AIDSAIDS
or acquired immunodeficiency syndrome,
fatal disease caused by a rapidly mutating retrovirus that attacks the immune system and leaves the victim vulnerable to infections, malignancies, and neurological disorders. It was first recognized as a disease in 1981.
..... Click the link for more information.
, cystic fibrosiscystic fibrosis
, inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males.
..... Click the link for more information.
, blepharospasm (uncontrolled rapid blinking), and snake bite.
The Columbia Electronic Encyclopedia™ Copyright © 2013, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/

orphan drug

[¦ȯr·fən ′drəg]
(pharmacology)
A pharmaceutical developed to treat a disease that afflicts relatively few people.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
The study demonstrates a decades-long pattern of flexibility in the FDA's review of orphan drugs.
In 1985, inspired by the fact that, within two years of passage of the Orphan Drug Act, 54 orphan drugs were under development or already approved, Congress decided to extend the Act's authorization of research grants and expand its protection of marketing rights to all orphan drugs rather than just unpatentable ones.
WASHINGTON -- Incentives incorporated in the Orphan Drug Act have helped with the clearance of over 250 such medications over the last two decades, according to the Food and Drug Administration.
Of the 64 orphan drugs approved for use, five lost their exclusivity this year: Chenix, made by Solvay Pharmaceuticals of Marietta, Ga.; Opticrom, by Fisons Corp., Rochester, N.Y.; Trexan, Du Pont Merck Pharmaceuticals, Wilmington, Del.; Pentam, Fujisawa Pharmaceutical Corp., Deerfield, Ill.; and Panhematin, Abbott Laboratories, Abbott Park, Ill.
Orphan Drug Survey 1992 1991(*) 1989 SUMMARY OF SURVEY RESULTS Active designations 488 422 299 Approved medicines 64 54 36 Orphan drugs development 189 176 133 Companies developing orphan drugs 132 120 85 SURVEY RESULTS BY DEVELOPMENT STATUS Phase I 17 20 15 Phase I/II 10 4 6 Phase II 61 49 39 Phase II/III 6 14 8 Phase III 97 86 61 Phase III completed 1 0 0 Phase III/application submitted 1 0 1 Applications submitted 46 50 39 Applications pending 0 0 1 Clinical trial status unidentified 3 9 2 RESEARCH PROJECTS(**) 242 232 172 RESULTS BY DISEASE CATEGORY AIDS and related conditions 20 24 18 Cancer 58 54 37 Childhood diseases 50 46 38 Diseases of women 17 12 9 Genetic disorders 35 31 28 Neuromuscular disorders 15 11 10 (*)There was no comparable survey in 1990.
The law drew complaints that, in rare cases, it was letting orphan drug manufacturers profit without challenge.
According to a report recently released by the Pharmaceutical Manufacturers Association, in cooperation with the Food and Drug Administration's Office of Orphan Products Development and the National Organization for Rare Disorders, 133 orphan drugs that combat 96 rare diseases are currently being developed.
Orphan drugs form a niche yet considerably profitable segment of the pharmaceutical industry.
Whereas orphan drugs get 10 years of exclusivity in Europe, plus extra time for pediatric indications.
[ClickPress, Tue Mar 12 2019] Market Research Reports Search Engine (MRRSE) has recently updated its massive report catalogue by adding a fresh study titled " Orphan Drugs Market Projections & Future Opportunities Recorded for the Period until 2025".
The Orphan Drug Report 2017 also found that only three in ten OD developers are still classified as biotech SMEs.
London, United Kingdom, June 27, 2016 --(PR.com)-- SMi Group's 5th annual conference on Orphan Drugs and Rare Diseases returns to London this Autumn and will explore how payers, pharmaceutical, biotech and patient organisations are preparing to participate in and leverage the growing orphan drugs and rare diseases industry.